“Our ability to perform both healthy volunteer trials as well as specialty trials with fullservices will garner efficiencies and drive quality for our partners” said Amy Young, vice president and general manager at DCR. “As research trends continue to involve patient studies earlier in the trial process, the ability to have real-time access to accurate data from a single organization becomes increasingly important.”
Employing software and fully validated systems, the data management services group demonstrates DCR’s ongoing commitment to offer best-in-class development capabilities. DCR has conducted more than 90 early clinical trials in more than 1,000 patients and healthy normal volunteers since 2009, including specialty populations and first-in-human studies. DCR now operates 122beds across two Phase I units in Minneapolis, Minn. and Denver, Colo.
The data management services team will be led by Michael Kreuter, director of DCR, who is located in Denver.
“Data integrity and patient safety are critical in Phase I clinical trial work,” saidKreuter. “We are building on DCR’s solid track record in those areas with a full range of data services necessary for early clinical work.”
Features of the data services group include:
Programmed systems using guidance from CDISC, ICH and other current guides
Client standards, which can be customized and used for future studies
Delivery of final datasets in industry standards including:
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.